Ondansetron EQL Pharma Approved

The pharmaceutical Ondansetron EQL Pharma tablets 4mg and 8mg have been approved by the Swedish Medical Products Agency for sale in Sweden. Approval is also expected soon for Denmark.

Ondansetron EQL Pharma is by prescription only and is used in the treatment of nausea and vomiting in connection with radiation therapy or chemotherapy. It is also used in prevention of nausea and vomiting in connection with surgical operations.

Ondansetron EQL Pharma has a launch date in the company's first financial quarter next year. The markets in Sweden and Denmark currently have sales of approximately SEK 15m and have between three and six active competitors per market.

For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 17 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2021 and beyond. The business is currently entirely focused on prescription drugs. EQL Pharma AB conducts its operations in Lund, employs 10 people and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.